Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.08Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 2.97%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in Fanapt's commercial performance and strategic expansions in sales force and pipeline development. However, challenges such as increased net loss, declining PONVORY sales, and potential future declines in HETLIOZ sales due to generic competition weigh against these positives.Company Guidance
During the Vanda Pharmaceuticals Q1 2025 earnings call, the company highlighted several key metrics and strategic initiatives. Fanapt's commercial growth was notable, with total prescriptions increasing by approximately 14% compared to Q1 2024, and new patient starts nearly tripling in the same period. The weekly prescriptions for Fanapt surpassed 2,000 by the end of April, marking it as one of the fastest-growing atypical antipsychotics. Vanda's revenue for Q1 2025 was $50 million, a 5% increase from the previous year, driven primarily by Fanapt sales which rose by 14% to $23.5 million. The company also expanded its sales force for Fanapt and PONVORY, reflecting a strategic push in marketing efforts. Additionally, Vanda has several regulatory milestones, including NDA filings for Tradipitant and Bysanti, and anticipates significant future growth potential with a projected total revenue for 2025 between $210 million and $250 million.Fanapt Commercial Growth
Fanapt's commercial growth has accelerated, reaching multi-year highs with weekly prescriptions surpassing 2,000 at the end of April. Total prescriptions increased by approximately 14% and net product sales increased by 14% compared to the same quarter last year.
Pipeline Development Success
Recent new drug application filings for Tradipitant and Bysanti indicate a strong and productive research and development pipeline, with multiple drugs in various stages of regulatory approval.
Expansion of Sales Force
Vanda has expanded its psychiatry sales force to approximately 300 representatives to support the growth of Fanapt and other products.
Maintained Market Share
HETLIOZ continues to retain the largest portion of market share despite generic competition for over two years.
Financial Guidance and Cash Reserves
Vanda expects total revenues from Fanapt, HETLIOZ, and PONVORY of between $210 million and $250 million. Year-end 2025 cash is projected to be between $280 million and $320 million.
VNDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VNDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $4.38 | $4.22 | -3.65% |
Feb 13, 2025 | $4.70 | $4.42 | -5.96% |
Nov 06, 2024 | $4.89 | $5.02 | +2.66% |
Jul 31, 2024 | $5.84 | $5.64 | -3.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vanda Pharmaceuticals Inc. (VNDA) report earnings?
Vanda Pharmaceuticals Inc. (VNDA) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Vanda Pharmaceuticals Inc. (VNDA) earnings time?
Vanda Pharmaceuticals Inc. (VNDA) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNDA EPS forecast?
VNDA EPS forecast for the fiscal quarter 2025 (Q2) is -0.36.